Figure 5 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance

Figure 5 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance

<p>A proposed model of ATRi resistance caused by SMG8/9 loss of function.</p>

Αποθηκεύτηκε σε:

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριος συγγραφέας:	Marta J. Llorca-Cardenosa (14961612) (author)
Άλλοι συγγραφείς:	Lauren I. Aronson (14961615) (author), Dragomir B. Krastev (14961618) (author), Jadwiga Nieminuszczy (14961621) (author), John Alexander (14961624) (author), Feifei Song (14961627) (author), Malgorzata Dylewska (14961630) (author), Ronan Broderick (14961633) (author), Rachel Brough (14961636) (author), Astrid Zimmermann (14961639) (author), Frank T. Zenke (14961642) (author), Bora Gurel (14961645) (author), Ruth Riisnaes (14961648) (author), Ana Ferreira (14961651) (author), Theodoros Roumeliotis (14961654) (author), Jyoti Choudhary (14961657) (author), Stephen J. Pettitt (14952601) (author), Johann de Bono (14961660) (author), Andres Cervantes (14961663) (author), Syed Haider (14961666) (author), Wojciech Niedzwiedz (14961669) (author), Christopher J. Lord (14952616) (author), Irene Y. Chong (14961672) (author)
Έκδοση:	2025
Θέματα:	Cancer Molecular and Cellular Biology Therapeutic Research and Development DNA Damage and Repair DNA repair Drug Mechanisms Drug Resistance Gastrointestinal Cancers Stomach cancer
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια

Figure 1 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
ανά: Marta J. Llorca-Cardenosa (14961612)
Έκδοση: (2025)

Figure 2 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
ανά: Marta J. Llorca-Cardenosa (14961612)
Έκδοση: (2025)

Figure 3 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
ανά: Marta J. Llorca-Cardenosa (14961612)
Έκδοση: (2025)

Figure 4 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
ανά: Marta J. Llorca-Cardenosa (14961612)
Έκδοση: (2025)

Supplementary Table S2 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
ανά: Arun Kanakkanthara (14937731)
Έκδοση: (2025)

Supplementary Table S3 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
ανά: Arun Kanakkanthara (14937731)
Έκδοση: (2025)

Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
ανά: Long Jiang (14956159)
Έκδοση: (2025)

Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
ανά: Long Jiang (14956159)
Έκδοση: (2025)

Supplementary Table from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
ανά: Long Jiang (14956159)
Έκδοση: (2025)

Supplementary Figure S9 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
ανά: Chuandong Geng (17315310)
Έκδοση: (2025)

Supplementary Table S9 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
ανά: Chuandong Geng (17315310)
Έκδοση: (2025)

Supplementary Data 1 from Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer
ανά: Kavya Ramkumar (16474203)
Έκδοση: (2025)

Supplementary Data from SENP1 Decreases RNF168 Phase Separation to Promote DNA Damage Repair and Drug Resistance in Colon Cancer
ανά: Min Wei (16918572)
Έκδοση: (2025)

Supplementary Data from SENP1 Decreases RNF168 Phase Separation to Promote DNA Damage Repair and Drug Resistance in Colon Cancer
ανά: Min Wei (16918572)
Έκδοση: (2025)

Supplementary Figure 9 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
ανά: Biagio Ricciuti (14951247)
Έκδοση: (2025)

Supplementary Figure S1 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
ανά: Chuandong Geng (17315310)
Έκδοση: (2025)

Supplementary Figure S10 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
ανά: Chuandong Geng (17315310)
Έκδοση: (2025)

Supplementary Figure S11 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
ανά: Chuandong Geng (17315310)
Έκδοση: (2025)

Supplementary Figure S12 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
ανά: Chuandong Geng (17315310)
Έκδοση: (2025)

Supplementary Figure S13 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
ανά: Chuandong Geng (17315310)
Έκδοση: (2025)

Supplementary Figure S14 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
ανά: Chuandong Geng (17315310)
Έκδοση: (2025)

Supplementary Figure S15 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
ανά: Chuandong Geng (17315310)
Έκδοση: (2025)

Supplementary Figure S16 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
ανά: Chuandong Geng (17315310)
Έκδοση: (2025)

Supplementary Figure S17 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
ανά: Chuandong Geng (17315310)
Έκδοση: (2025)

Supplementary Figure S18 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
ανά: Chuandong Geng (17315310)
Έκδοση: (2025)

Supplementary Figure S19 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
ανά: Chuandong Geng (17315310)
Έκδοση: (2025)

Supplementary Figure S2 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
ανά: Chuandong Geng (17315310)
Έκδοση: (2025)

Supplementary Figure S20 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
ανά: Chuandong Geng (17315310)
Έκδοση: (2025)

Supplementary Figure S21 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
ανά: Chuandong Geng (17315310)
Έκδοση: (2025)

Supplementary Figure S3 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
ανά: Chuandong Geng (17315310)
Έκδοση: (2025)

Supplementary Figure S4 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
ανά: Chuandong Geng (17315310)
Έκδοση: (2025)

Supplementary Figure S5 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
ανά: Chuandong Geng (17315310)
Έκδοση: (2025)

Supplementary Figure S6 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
ανά: Chuandong Geng (17315310)
Έκδοση: (2025)

Supplementary Figure S7 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
ανά: Chuandong Geng (17315310)
Έκδοση: (2025)

Supplementary Figure S8 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
ανά: Chuandong Geng (17315310)
Έκδοση: (2025)

Supplementary Table S1 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
ανά: Chuandong Geng (17315310)
Έκδοση: (2025)

Supplementary Table S10 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
ανά: Chuandong Geng (17315310)
Έκδοση: (2025)

Supplementary Table S11 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
ανά: Chuandong Geng (17315310)
Έκδοση: (2025)

Supplementary Table S12 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
ανά: Chuandong Geng (17315310)
Έκδοση: (2025)

Supplementary Table S13 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
ανά: Chuandong Geng (17315310)
Έκδοση: (2025)

Cannot write session to /tmp/vufind_sessions/sess_pp4vud8t1rqib9a7a3tmq3t21l